Practical Derm

A monthly publication that covers medical care, cosmetic advancements, and practice management for clinicians in the field. #dermatology #dermtwitter

[Practical Derm @Practical_Derm]

🚨 The October issue of Practical Dermatology is now online! - Explore The Evolving Landscape of Atopic Dermatitis, featuring expert perspectives on treatment options, patient-reported outcomes, and emerging considerations in care➡️ https://t.co/NPXwZDWX70
#PracticalDermatology #AtopicDermatitis #Dermatology #SkinHealth #DermatologyResearch

[Practical Derm @Practical_Derm]

🎙️👨‍⚕️NEW DISEASE DEEP DIVE: Walter Liszewski, MD, and Naiem Issa, MD, discuss how to diagnose chronic spontaneous urticaria, avoid unnecessary testing, and apply updated treatment recommendations, including newer systemic therapies.✨💉

🎧 Listen here ➡️ https://t.co/6n7EJL2iyJ

[Practical Derm @Practical_Derm]

📊👀NEW DATA: The investigational IL-23p19 inhibitor ORKA-001 produced high rates of complete skin clearance through week 28 in adults with moderate-to-severe plaque psoriasis who received their last dose at week 4, according to results from the phase 2a EVERLAST-A trial presented in a research poster at the 2026 Fall Clinical Dermatology Conference ➡️ https://t.co/9HEuxFrgxf

[Practical Derm @Practical_Derm]

👨‍⚕️👩‍⚕️👨‍⚕️👩‍⚕️📊PANEL PROPOSES MOLLUSCUM TREATMENT ALGORITHM: A pediatric dermatology expert panel has proposed a practical treatment algorithm for molluscum contagiosum that emphasizes disease severity, family preferences, and shared decision-making ➡️ https://t.co/u8Abr5jRgm

[Practical Derm @Practical_Derm]

NEW ACQUISITION: Galderma to Acquire ZO Skin Health for $1.5 Billion: Galderma announced an agreement to acquire ZO Skin Health for $1.5 billion, a move it says will expand its dermatological skincare business and strengthen its presence in the physician-dispensed skincare market.

Read more ➡️ https://t.co/Vc8P5hJtr9

[Practical Derm @Practical_Derm]

📊🩺 NEW DATA: Researchers have announced new phase 1b data for SYX-5219, an investigational oral PKM2 modulator, which showed improvements in atopic dermatitis severity and itch over 6 weeks ➡️ https://t.co/GkIIrRSxs9

#SkinHealth #PKM2Modulator #MedicalResearch #ClinicalTrials #Dermatology #AtopicDermatitis #ClinicalResearch

[Practical Derm @Practical_Derm]

📊 🔍 ICYMI: Dr. Shawn Kwatra analyzes new data from the phase 3b ADtouch study for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas ➡️ https://t.co/JA8t3n7rza #AtopicDermatitis #SkinHealth #SkinDisease #ClinicalResearch

[Practical Derm @Practical_Derm]

👀 📊GAPS IN ATOPIC DERM SKIN MODELS: A 2026 expert consensus review published in the Journal of Investigative Dermatology examined the advantages and limitations of human-based in vitro models for atopic dermatitis (AD) ➡️ https://t.co/EEBMcxOBQj #SkinResearch #Dermatology #SkinHealth #AtopicDermatitis

[Practical Derm @Practical_Derm]

🎤👨‍⚕️📊NEW: Study investigator Dr. Shawn Kwatra talked with Practical Dermatology about new Phase 3b ADtouch data for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) and how it may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas 👉 https://t.co/jgShF6rsYz

[Practical Derm @Practical_Derm]

🚨🆕 The FDA has approved Rhapsido (remibrutinib) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines 🔬👉https://t.co/MbStJj2bgm

[Practical Derm @Practical_Derm]

🏆 NEWS: Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) ZORYVE® (roflumilast) HCP cream 0.15% has received Marie Claire’s inaugural Best Prescription Skin Solution Award ➡️ https://t.co/plJAecKKV6

#Dermatology #AtopicDermatitis #Eczema #ZORYVE #Dermatology

[Practical Derm @Practical_Derm]

🌿 EARLY ENVIRONMENTAL FACTORS FOR AD: Environmental factors may play an important role in pediatric atopic dermatitis, according to new research ➡️ https://t.co/zV1NB4IES8 #AtopicDermatitis #PediatricDermatology #Dermatology #Eczema

[Practical Derm @Practical_Derm]

📊👨‍⚕️🎤ICOTROKINRA UPDATE: New two-year phase 3 ICONIC-TOTAL data presented at EADV 2026 showed sustained responses with oral icotrokinra among adults and adolescents with plaque psoriasis involving high-impact sites.

Read more ➡️ https://t.co/UDvmA9EFlR

#Icotrokinra #PlaquePsoriasis #EADV2026 #SkinHealth

[Practical Derm @Practical_Derm]

🩺👉 SKIN MINUTE: Linda Stein Gold, MD, discusses a new pooled post hoc analysis evaluating the efficacy and safety of #tapinarof cream 1% in the treatment of atopic dermatitis ➡️ https://t.co/aQksvgM8bA #Tapinarof #DermatologyResearch #AtopicDermatitis #SkinHealth

[Practical Derm @Practical_Derm]

📊🎤👨‍⚕️LITIFILIMAB MEETS PRIMARY ENDPOINT: Phase 2 Part A of the AMETHYST study met its primary endpoint, with more patients receiving litifilimab achieving clear or almost clear skin by CLA-IGA-R erythema score at week 16 than those receiving placebo ➡️ https://t.co/kDdgyWuRtk
#Dermatology #Lupus #ClinicalTrials #SkinHealth #MedTwitter #Aesthetics

[Practical Derm @Practical_Derm]

🔬 NEW DAX DATA: Evaluated doses of daxdilimab significantly improved CLASI-A scores versus placebo at week 24, according to new data presented at 2026 EADV Congress in Vienna ➡️ https://t.co/whrIGSm0zS

#Dermatology #DiscoidLupus #CutaneousLupus #ClinicalTrials

[Practical Derm @Practical_Derm]

💊🧴SKIN TO BELIEVE IN: Simone Biles is sharing her experience with seborrheic dermatitis and eczema as part of Arcutis Biotherapeutics’ new Skin to Believe In campaign ➡️ https://t.co/qVvRKUxM4e #Dermatology #SeborrheicDermatitis #AtopicDermatitis #Eczema #SkinHealth #DermatologyNews

[Practical Derm @Practical_Derm]

💉🤰NEW: Biologic therapy was not associated with increased adverse pregnancy outcomes among patients with psoriasis in a large real-world cohort study published in the Journal of the American Academy of Dermatology 👉 https://t.co/jVPXGRYQ5O #PsoriasisCare #PatientSafety #DermatologyResearch #BiologicTherapy #MedicalResearch

[Practical Derm @Practical_Derm]

🩺👨‍⚕️👩‍⚕️MANAGING DIFFICULT TREATMENT COMBOS FOR PSO: During a case-based session at the Science of Skin Summit, Scott Drew, DO; April Armstrong, MD, MPH; and Erin Boh, MD, PhD, explored how complex psoriasis presentations can require clinicians to move beyond standardized treatment algorithms and individualize management ➡️ https://t.co/awg02BawHH #PsoriasisCare #SkinHealth #SkinSummit #ClinicalDermatology

[Practical Derm @Practical_Derm]

FDA Approves First Treatment for Ataxia-Telangiectasia: The US Food and Drug Administration (FDA) has approved Aqneursa (levacetylleucine; IntraBio) for the treatment of adults and pediatric patients with ataxia-telangiectasia (A-T) who weigh at least 15 kg, providing the first FDA-approved treatment for the rare multisystem disorder.

Read more ➡️ https://t.co/wKanY2ap30 #AtaxiaTelangiectasia #RareDisease #RareDisorders #FDAApproval #Dermatology